Infectious Disease Advisor news story
Although mpox vaccination reduces disease severity, protection appears to diminish after 2 years, indicating that recent immunization may be more effective, according to study results presented at CROI 2026.
While previous research suggests that mpox vaccination attenuates disease severity, these studies often lack adjustment for important variables such as age and health status. To help fill this knowledge gap, researchers examined the relationship between mpox vaccination and disease severity with adjustment for potential confounders. They also assessed temporal associations between vaccination date and mpox severity.
Read the full news story here.
/Infectious Disease Advisor requires free registration if more than 5 articles are viewed per month/
View all Infectious Disease Advisor reports from CROI 2026
Source : Infectious Disease Advisor
Related HIV and Co-Infections News
-
ECDC launches new monthly mpox surveillance report as transmission continues in Europe
-
NDTV: Mpox can infect and replicate in the brain, NIH researchers say in fatal HIV case
-
[Press release] University of Barcelona: People with HIV did not show more severe clinical symptoms during the 2022 mpox outbreak in Spain
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.